OTC · SAGD
South American Gold Corp.
$0.00$0.00 (0.0%)
South American Gold Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · ERGO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Entia Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Entia Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
South American Gold Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Biostax Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
DNAPrint Genomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
RepliCel Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
$0.00$0.00 (0.0%)
Statera Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.62% below the high.
$0.00$0.00 (0.0%)
AVAX Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Better Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Panacos Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
